Statement by Blue Earth Diagnostics on COVID-19 click here for more information

Latest News From Blue Earth Diagnostics


Blue Earth Diagnostics and Siemens’ PETNET Solutions Announce Commercial Availability of AxuminTM (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer

Blue Earth Diagnostics and Siemens’ PETNET Solutions Announce Commercial Availability of AxuminTM (Fluciclovine F 18)…

Blue Earth Diagnostics Announces AxuminTM (Fluciclovine F 18) Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

- Axumin Recently FDA-approved to Detect Recurrent Prostate Cancer -   BURLINGTON, Mass. and OXFORD,…

FDA approves new diagnostic imaging agent to detect recurrent prostate cancer

The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection.…

U.S. FDA Approves Blue Earth Diagnostics’ AxuminTM (Fluciclovine F 18) Injection after Priority Review for PET Imaging of Recurrent Prostate Cancer

OXFORD, England and BURLINGTON, Mass., May 31, 2016 – Blue Earth Diagnostics Ltd., a molecular…

Blue Earth Diagnostics Announces Opening of U.S. Office and Expansion of Management Team

OXFORD, England, and BURLINGTON, Mass. – May 11, 2016 – Blue Earth Diagnostics, a molecular…

Blue Earth Diagnostics begins fluciclovine (18F) studies in Recurrent Prostate Cancer Patients

Blue Earth Diagnostics Ltd. (“BED”), a private diagnostics company, announces the commencement of the BED-004,…

Blue Earth Diagnostics and Norsk medisinsk syklotronsenter AS announce manufacturing and distribution partnership for Fluciclovine (18F)

Blue Earth Diagnostics Ltd. (“BED”), a private diagnostics company, announced that it agreed a new…

Blue Earth Diagnostics and Siemens’ PETNET Solutions announce FDA acceptance of NDA filing for fluciclovine

Blue Earth Diagnostics Ltd. (“BED”), a private diagnostics company, announced that a New Drug Application…

Blue Earth Diagnostics receives £18M Series B Funding from Syncona Partners and establishes Blue Earth Diagnostics Inc

Blue Earth Diagnostics Ltd (“BED”), a private diagnostics company, announces today that it has received…

Blue Earth Diagnostics granted US and European orphan drug designation for fluciclovine (18F) in the diagnosis of glioma

Blue Earth Diagnostics Ltd (“BED”), a private diagnostics company, announces today that it has received…

Blue Earth Diagnostics signs an agreement with Siemens’ PETNET Solutions to manufacture and distribute prostate cancer PET imaging agent

Blue Earth Diagnostics Ltd (“BED”), a private diagnostics company, has entered into an exclusive agreement…

Syncona announces the formation of Blue Earth Diagnostics, a company developing PET agents for the detection of recurrent prostate cancer

Syncona Partners LLP (“Syncona”) announces a £12.8 million investment in Blue Earth Diagnostics Ltd (“BED”),…